Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.
| Revenue (Most Recent Fiscal Year) | $80.00M |
| Net Income (Most Recent Fiscal Year) | $-74.88M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.96 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -25.38% |
| Return on Assets (Trailing 12 Months) | -24.15% |
| Current Ratio (Most Recent Fiscal Quarter) | 31.35 |
| Quick Ratio (Most Recent Fiscal Quarter) | 31.35 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.21 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.18 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.21 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 76.30M |
| Free Float | 70.73M |
| Market Capitalization | $298.32M |
| Average Volume (Last 20 Days) | 1.79M |
| Beta (Past 60 Months) | 3.05 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 89.83% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |